AP2048A - Diazepinoindole derivatives as kinase inhibitors - Google Patents

Diazepinoindole derivatives as kinase inhibitors

Info

Publication number
AP2048A
AP2048A AP2005003353A AP2005003353A AP2048A AP 2048 A AP2048 A AP 2048A AP 2005003353 A AP2005003353 A AP 2005003353A AP 2005003353 A AP2005003353 A AP 2005003353A AP 2048 A AP2048 A AP 2048A
Authority
AP
ARIPO
Prior art keywords
kinase inhibitors
diazepinoindole
derivatives
diazepinoindole derivatives
kinase
Prior art date
Application number
AP2005003353A
Other languages
English (en)
Other versions
AP2005003353A0 (en
Inventor
Sacha Ninkovic
Michael John Bennett
Eugene Yuanjin Rui
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AP2005003353A0 publication Critical patent/AP2005003353A0/xx
Application granted granted Critical
Publication of AP2048A publication Critical patent/AP2048A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AP2005003353A 2003-01-09 2004-01-05 Diazepinoindole derivatives as kinase inhibitors AP2048A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43939603P 2003-01-09 2003-01-09
PCT/IB2004/000026 WO2004063198A1 (fr) 2003-01-09 2004-01-05 Derives de diazepinoindole en tant qu'inhibiteurs de kinase

Publications (2)

Publication Number Publication Date
AP2005003353A0 AP2005003353A0 (en) 2005-09-30
AP2048A true AP2048A (en) 2009-09-24

Family

ID=32713475

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2005003353A AP2048A (en) 2003-01-09 2004-01-05 Diazepinoindole derivatives as kinase inhibitors

Country Status (35)

Country Link
US (3) US6967198B2 (fr)
EP (2) EP1585749B1 (fr)
JP (1) JP3990718B2 (fr)
KR (1) KR100697746B1 (fr)
CN (1) CN1759118B (fr)
AP (1) AP2048A (fr)
AT (1) ATE404564T1 (fr)
AU (1) AU2004203977B2 (fr)
BR (1) BRPI0406701A (fr)
CA (1) CA2512683C (fr)
CR (1) CR7899A (fr)
CY (1) CY1108408T1 (fr)
DE (1) DE602004015724D1 (fr)
DK (1) DK1585749T3 (fr)
EA (1) EA009337B1 (fr)
EC (1) ECSP055911A (fr)
ES (1) ES2309484T3 (fr)
GE (1) GEP20084367B (fr)
HK (1) HK1086257A1 (fr)
HR (1) HRP20050624A2 (fr)
IL (1) IL169082A (fr)
IS (1) IS7884A (fr)
MA (1) MA27703A1 (fr)
MX (1) MXPA05007352A (fr)
NO (1) NO20053775L (fr)
NZ (1) NZ540638A (fr)
OA (1) OA13017A (fr)
PL (1) PL378372A1 (fr)
PT (1) PT1585749E (fr)
RS (1) RS20050522A (fr)
SI (1) SI1585749T1 (fr)
TN (1) TNSN05176A1 (fr)
UA (1) UA80733C2 (fr)
WO (1) WO2004063198A1 (fr)
ZA (1) ZA200504674B (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1467730A4 (fr) * 2002-01-22 2010-03-10 Univ California Ligands non steroidiens pour le recepteur des corticoides, compositions et utilisations desdits ligands
RS20050522A (en) * 2003-01-09 2007-12-31 Pfizer Inc., Protein kinase inhibiting tricyclic compounds that increase the effects of anti-neoplastic agents and therapeutic radiation
AU2006215413B2 (en) * 2005-02-18 2010-10-07 Astrazeneca Ab Method for determining responsiveness to CHK1 inhibitors
EP1869020B1 (fr) 2005-03-29 2010-12-01 ICOS Corporation Derives d'uree d'heteroaryle utilises pour inhiber chk1
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
WO2007002931A2 (fr) 2005-06-29 2007-01-04 Threshold Pharmaceuticals, Inc. Prodrogues d'alkylateur de phosphoramidate
EP1928907A4 (fr) 2005-08-15 2009-03-11 Univ California Ligands fas actives par vegf
EP1942193A4 (fr) 2005-08-25 2010-10-27 Ube Industries PROCÉDÉ DE PRODUCTION D ACIDE (S OU R)-a -AMINÉ OPTIQUEMENT ACTIF OU D ESTER D ACIDE (S OU R)-a-AMINÉ OPTIQUEMENT ACTIF
EP1916896A4 (fr) * 2005-08-26 2010-08-11 Univ California Antiandrogenes non steroidiens
WO2007113647A1 (fr) * 2006-04-04 2007-10-11 Pfizer Products Inc. Formes polymorphes de (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-méthyl-1h-pyrazol-4υl)-1-oxo-2,6-dihydro-1h-[1,2]diazépino[4,5,6-cd]indol-8-yl)acétamide
US20090312280A1 (en) * 2006-04-04 2009-12-17 Pfizer Inc. Combination therapy of (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4-yl)-1-oxo-2,6-dihydro-1h-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide
MX2009005300A (es) * 2006-11-17 2009-06-08 Schering Corp Combinacion de un inhibidor de acido desoxirribonucleico polimerasa-alfa y un inhibidor de una cinasa de punto de verificacion para trastornos proliferativos.
US8158656B2 (en) * 2008-05-16 2012-04-17 Shenzhen Chipscreen Biosciences Ltd. 2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
ES2378513T3 (es) * 2008-08-06 2012-04-13 Pfizer Inc. Compuestos 2-heterociclilamino piracinas sustituidas en posición 6 como inhibidores de CHK-1
EP2346881A1 (fr) * 2008-10-10 2011-07-27 Priaxon AG Nouveaux composés qui modulent l'activité kinase
US8314108B2 (en) 2008-12-17 2012-11-20 Eli Lilly And Company 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts
US8663210B2 (en) 2009-05-13 2014-03-04 Novian Health, Inc. Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy
US8211901B2 (en) 2009-05-22 2012-07-03 Shenzhen Chipscreen Biosciences Ltd. Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
CN101906076B (zh) 2009-06-04 2013-03-13 深圳微芯生物科技有限责任公司 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用
CA2835195A1 (fr) 2011-05-06 2012-11-15 Zafgen, Inc. Composes de sulfonamide tricycliques et leurs procedes de fabrication et d'utilisation
JP2015500885A (ja) * 2011-12-22 2015-01-08 スレッショルド ファーマシューティカルズ，インコーポレイテッド 癌を治療するためのｃｈｋ１阻害剤と組み合わせた低酸素活性化プロドラッグの投与
CN106083849A (zh) 2011-12-31 2016-11-09 百济神州有限公司 作为parp抑制剂的稠合的四元或五元环吡啶并酞嗪酮类化合物
SG11201401726VA (en) 2011-12-31 2014-10-30 Beigene Ltd Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors
CN102746211B (zh) * 2012-06-27 2015-05-27 上海泰坦化学有限公司 一种取代吲哚-3-甲醛类化合物的制备方法
TWI633107B (zh) * 2013-05-22 2018-08-21 開曼群島商百濟神州生物科技有限公司 作為ｐａｒｐ抑制劑的稠合四或五環二氫二氮呯并咔唑酮
WO2015013579A1 (fr) 2013-07-26 2015-01-29 Update Pharma Inc. Compositions permettant d'améliorer l'avantage thérapeutique du bisantrène
US10071109B2 (en) 2013-11-06 2018-09-11 Molecular Templates, Inc. Predictive biomarker for hypoxia-activated prodrug therapy
PL3157566T3 (pl) 2014-06-17 2019-10-31 Vertex Pharma Metoda leczenia nowotworu przy użyciu kombinacji inhibitorów chk1 i atr
WO2017032289A1 (fr) 2015-08-25 2017-03-02 Beigene, Ltd. Procédé de préparation d'inhibiteur de parp, formes cristallines et leurs utilisations
WO2017059357A1 (fr) 2015-09-30 2017-04-06 Vertex Pharmaceuticals Incorporated Méthode de traitement du cancer utilisant une association d'agents endommageant l'adn et d'inhibiteurs de l'atr
US11202782B2 (en) 2016-09-27 2021-12-21 Beigene, Ltd. Treatment cancers using a combination comprising PARP inhibitors
JP6541635B2 (ja) * 2016-10-28 2019-07-10 ベイジーン リミテッド Ｐａｒｐ阻害剤としての縮合四環式または縮合五環式ジヒドロジアゼピノカルバゾロン
WO2018157794A1 (fr) 2017-02-28 2018-09-07 Beigene, Ltd. Formes cristallines de sels de dihydrodiazépinocarazolones téra-cycliques ou penta-cycliques fusionnés, et leurs utilisations
US11661581B2 (en) * 2017-05-25 2023-05-30 University Of Massachusetts Use of CDK inhibitors to enhance growth and self-renewal of progenitor cells
BR112020005489A2 (pt) * 2017-09-22 2020-09-24 Jubilant Epipad Llc, composto da fórmula (i), composto de fórmula (ii), composto de fórmula (iii), processo de preparação de compostos de fórmula (i), processo de preparação de compostos de fórmula (ii), processo de preparação de compostos de fórmula (iii), composição farmacêutica, método para inibir uma ou mais famílias pad em uma célula, método para tratar uma afeção mediada por um ou mais pads, utilização do composto, método para o tratamento e/ou prevenção de uma afeção mediada por um ou mais distúrbios da família pad, método para o tratamento de artrite reumatoide e método de tratamento de câncer
EP3461480A1 (fr) 2017-09-27 2019-04-03 Onxeo Combinaison d'inhibiteurs de point de contrôle du cycle cellulaire de réponse à un dommage à l'adn et de belinostat pour traiter le cancer
JP2022523028A (ja) * 2019-01-25 2022-04-21 ヌメディー， インコーポレイテッド 特発性肺線維症を処置するための方法
WO2021018298A1 (fr) * 2019-08-01 2021-02-04 南京明德新药研发有限公司 Composés acyloxime à sept chaînons indolo servant d'inhibiteurs de parp
WO2021104461A1 (fr) 2019-11-29 2021-06-03 南京明德新药研发有限公司 Dérivé de diazaindole et son utilisation en tant qu'inhibiteur de chk1
WO2022011458A1 (fr) * 2020-07-13 2022-01-20 Ontario Institute For Cancer Research (Oicr) Conjugués inhibiteurs de nicotinamide phosphoribosyltransférase (nampt) et leurs utilisations
JP2023537220A (ja) * 2020-07-31 2023-08-31 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド Ｐａｒｐ阻害剤としてのインドロヘプタアシルオキシム類似体の結晶及びその製造方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000042040A1 (fr) * 1999-01-11 2000-07-20 Agouron Pharmaceuticals, Inc. Inhibiteurs tricycliques de poly(adp-ribose) polymerases
WO2002044183A2 (fr) * 2000-12-01 2002-06-06 Guilford Pharmaceuticals Inc. Composes et leurs utilisations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9722320D0 (en) 1997-10-22 1997-12-17 Janssen Pharmaceutica Nv Human cell cycle checkpoint proteins
US6383744B1 (en) 1998-07-10 2002-05-07 Incyte Genomics, Inc. Human checkpoint kinase
JP2002526450A (ja) 1998-09-18 2002-08-20 スミスクライン・ビーチャム・コーポレイション Ｃｈｋ１キナーゼ阻害物質
AU7070800A (en) 1999-08-27 2001-03-26 Chiron Corporation Chimeric antisense oligonucleotides and cell transfecting formulations thereof
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
US6670167B1 (en) 1999-11-01 2003-12-30 Agouron Pharmaceuticals, Inc. Catalytic domain of the human effector cell cycle checkpoint protein kinase materials and methods for identification of inhibitors thereof
CA2385257A1 (fr) 1999-09-22 2001-03-29 Canbas Co., Ltd. Compositions et methodes d'inhibition de l'arret du cycle cellulaire g2 et de sensibilisation de cellules aux agents de degradation d'adn
US6211164B1 (en) 2000-03-10 2001-04-03 Abbott Laboratories Antisense oligonucleotides of the human chk1 gene and uses thereof
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
RS20050522A (en) * 2003-01-09 2007-12-31 Pfizer Inc., Protein kinase inhibiting tricyclic compounds that increase the effects of anti-neoplastic agents and therapeutic radiation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000042040A1 (fr) * 1999-01-11 2000-07-20 Agouron Pharmaceuticals, Inc. Inhibiteurs tricycliques de poly(adp-ribose) polymerases
WO2002044183A2 (fr) * 2000-12-01 2002-06-06 Guilford Pharmaceuticals Inc. Composes et leurs utilisations

Also Published As

Publication number Publication date
NO20053775L (no) 2005-09-16
NZ540638A (en) 2007-12-21
EA200500893A1 (ru) 2006-02-24
HRP20050624A2 (en) 2006-02-28
KR20050092397A (ko) 2005-09-21
CA2512683A1 (fr) 2004-07-29
EP1947102A1 (fr) 2008-07-23
AU2004203977B2 (en) 2010-06-17
ZA200504674B (en) 2006-07-26
MA27703A1 (fr) 2006-01-02
US7462713B2 (en) 2008-12-09
CY1108408T1 (el) 2014-02-12
WO2004063198A1 (fr) 2004-07-29
NO20053775D0 (no) 2005-08-08
US20070135415A1 (en) 2007-06-14
BRPI0406701A (pt) 2005-12-20
CR7899A (es) 2005-08-05
ATE404564T1 (de) 2008-08-15
CN1759118A (zh) 2006-04-12
ECSP055911A (es) 2005-11-22
IS7884A (is) 2005-06-09
EA009337B1 (ru) 2007-12-28
PL378372A1 (pl) 2006-04-03
UA80733C2 (en) 2007-10-25
US7132533B2 (en) 2006-11-07
US20050075499A1 (en) 2005-04-07
OA13017A (en) 2006-11-10
PT1585749E (pt) 2008-10-23
CA2512683C (fr) 2010-03-16
TNSN05176A1 (fr) 2007-06-11
DK1585749T3 (da) 2008-09-22
AP2005003353A0 (en) 2005-09-30
JP2006516274A (ja) 2006-06-29
HK1086257A1 (en) 2006-09-15
US6967198B2 (en) 2005-11-22
MXPA05007352A (es) 2006-02-17
KR100697746B1 (ko) 2007-03-22
ES2309484T3 (es) 2008-12-16
IL169082A (en) 2011-02-28
DE602004015724D1 (de) 2008-09-25
US20060004052A1 (en) 2006-01-05
JP3990718B2 (ja) 2007-10-17
SI1585749T1 (sl) 2008-10-31
CN1759118B (zh) 2010-12-08
GEP20084367B (en) 2008-05-13
EP1585749A1 (fr) 2005-10-19
RS20050522A (en) 2007-12-31
AU2004203977A1 (en) 2004-07-29
EP1585749B1 (fr) 2008-08-13

Similar Documents

Publication Publication Date Title
AP2048A (en) Diazepinoindole derivatives as kinase inhibitors
IL172132A0 (en) Thienopyridone derivatives as kinase inhibitors
IL165515A0 (en) Bisindolyl-maleimid derivatives as kinase inhibitors
IL173381A0 (en) 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
IL173380A0 (en) Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors
IL173200A0 (en) Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
AU2003271566A8 (en) Pyrrolopyrazines as kinase inhibitors
IL172375A0 (en) Chinazoline derivatives as aurora kinase inhibitors
TWI370127B (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
ZA200606683B (en) Pyrazolotriazines as kinase inhibitors
ZA200700181B (en) Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors
PL373649A1 (en) Kinase inhibitors
ZA200702394B (en) Indozolone derivatives as 11b-HSD1 inhibitors
SI1569907T1 (sl) Na nikotinamidu osnovani kinazni inhibitorji
IL175568A0 (en) Azole-based kinase inhibitors
HK1071758A1 (en) Pyrazolopyridines as cyclin dependent kinase inhibitors
EP1558609A4 (fr) Inhibiteurs de kinase
PL378116A1 (pl) Heterocykliczne inhibitory kinazy
EP1569907A4 (fr) Inhibiteurs de kinase a base de nicotinamide
ZA200703835B (en) Heterocyclic substituted bisarylurea derivatives as kinase inhibitors
AU2003232362A8 (en) 4-pyrazol-phenylalanine derivatives as ace-nep inhibitors
SI1483265T1 (sl) Drivati purina kot inhibitoriji kinaze
AU2003906917A0 (en) Imidazopyrazine-based kinase Inhibitors
SI1684750T1 (sl) aminoariloksazolne spojine kot inhibitorji tirozin kinaze